









Markets
/
Stocks
/
nasdaq-enlv
/

Enlivex Therapeutics Ltd

ENLV

1.160USD

0.0000.00%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

28.18MMarket Cap

LossP/E TTM



Enlivex Therapeutics Ltd

1.160

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Enlivex Therapeutics Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Enlivex Therapeutics Ltd's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 157 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Enlivex Therapeutics Ltd's Score

Industry at a Glance

Industry Ranking

157 / 392

Overall Ranking

304 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Enlivex Therapeutics Ltd Highlights

StrengthsRisks

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Undervalued

The company’s latest PE is -2.10, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 157.29K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 5.81.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

13.000

Target Price

+1081.82%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Enlivex Therapeutics Ltd is 5.38, ranking 373 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.38

Change



Financials

2.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.91

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

6.91

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Enlivex Therapeutics Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Enlivex Therapeutics Ltd is 7.20, ranking 152 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.10, which is -59.41% below the recent high of -0.85 and -49.83% above the recent low of -3.15.

Score

Industry at a Glance

Previous score

7.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 157/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Enlivex Therapeutics Ltd is 7.00, ranking 311 out of 392 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 7.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

13.000

Target Price

+1081.82%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Enlivex Therapeutics Ltd

ENLV

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Enlivex Therapeutics Ltd is 8.79, ranking 56 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.33 and the support level at 0.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.91

Change

-0.12

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(0)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.017

Buy

RSI(14)

63.551

Neutral

STOCH(KDJ)(9,3,3)

57.294

Buy

ATR(14)

0.093

High Vlolatility

CCI(14)

93.040

Neutral

Williams %R

29.420

Buy

TRIX(12,20)

1.124

Buy

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.110

Buy

MA10

1.112

Buy

MA20

1.040

Buy

MA50

0.949

Buy

MA100

0.999

Buy

MA200

1.065

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Enlivex Therapeutics Ltd is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 13.33%, representing a quarter-over-quarter decrease of 3.50%. The largest institutional shareholder is Catherine Wood, holding a total of 628.31K shares, representing 0.26% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Novik (Shai A)

858.77K

+10.95%

Havron (Abraham)

181.46K

+1.07%

Morgan Stanley Smith Barney LLC

173.63K

-20.77%

Renaissance Technologies LLC

Star Investors

157.29K

-6.59%

Citadel Advisors LLC

68.94K

Susquehanna International Group, LLP

54.85K

Two Sigma Investments, LP

44.98K

XTX Markets LLC

42.67K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Enlivex Therapeutics Ltd. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.55. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.